KV and Beijing Med-Pharm in Chinese Clindesse deal

USA-based drugmaker KV Pharmaceutical has entered into an agreement with China's Beijing Med-Pharm for exclusive Chinese marketing and distribution rights to Clindesse (clindamycin phosphate 2%), KV's proprietary vaginal cream prescription bacterial vaginosis treatment. The drug, which utilizes KV's Site Release technology, is expected to be the only one-time drug for this indication available in the country.

Under the terms of the agreement, financial details of which were not provided, Beijing Med-Pharm will be responsible for late-stage clinical development of the drug and its registration with the Chinese regulatory authorities.

Marc Hermelin, chairman of KV's board, said that the firm was keen to begin broadening its business base in China, adding that Beijing Med Pharma was an ideal partner for this expansion, in that it would allow it to access what it estimates will be a significant market.